Link to Join on Patreon
x
Before discussing today’s low risk high return potential, and Cathie Wood’s favorite Penny Stock let me provide you a quick update on Cassava Sciences.
There is no denying that a Short Seller paid Law firm and few scientists to defame Cassava Sciences. Short seller mean a person who is betting on the stock price going down… How can you expect anything neutral from a short seller. He paid everyone to write negative about cassasva sciences so he can make money. And now same story has been published by the Bloomberg. Bloomberg reported yesterday that:
“Cassava Short Sellers Reap $100 Million in August Stock Rout”
S3 Partners, a data power company published the data revealing the short interest of 350 Million dollars on SAVA. Mr. Ihor Dusaniwsky, Managing Director at S3 Partners LLC revealed via tweet, that approximately 5 Million shares were shorted representing 13% of SAVA’s float. During the third week of August around 152K shares worth 11 Million dollars were shorted.
We have already told our viewers about such petitions and Ambulance Chaser Lawyers backed by the shorter. These short positions’ holders actually plant and fund such petitions and Ambulance Chaser Lawyers to make the retail investors panic so that they could grab after the selloff amid negative news. And this is what happened with the Cassava Sciences last week. So one thing is cleared that these attempts of petition and Lawyers fueling the rumors are baseless and nothing to do with Cassava’s Simufilam results. So I believe this petition would also be kicked off by the FDA like other 98% petitions rejected by the FDA, and the stock price would surpass 100 dollars per share again once these tactics would take last breaths and Cassava Sciences will release the 12 months data in Q4, this year. In addition, Phase 3 trials would also validate Cassava’s stance over its Simufilam cognition and Biomarker data, as the company has announced its agreement with FDA on a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease. Remember, if there would be any doubt in Cassava’s 6 and 9 months and phase 2 data, FDA would never sign SPA agreement with Cassava Sciences for its Phase 3 studies.
The penny stock that I will be discussing today is Conformis, Inc. ticker symbol CFMS
It is currently trading near 1.6 and has a market cap of around 300 million dollars and around 108.32 million dollars as cash in hand. Meaning 36% of the market cap is represented by Cash in hand… Cathie Wood is betting big on Conformis Inc. and has bought more than 13 million shares for her 3d Printing ETF. Conformis is the 6th largest holding of Cathie Wood in her 3d printing etf. It can reach 3+ in 6 to 9 months time easily. This stock was first shared with our private discord members a few weeks ago when it was trading near 1.25 dollars….
DISCLAIMER: Note that I am not a financial adviser and you should do your own due diligence before making any decision. I just share my views. I do not recommend basing any investment decisions on my videos. My videos are only made for educational and entertainment purposes.
